Growth hormone and insulin-like growth factor-I and mesangial matrix in uremic rats

Jen Jar Lin, Richard N. Fine, Frederick J. Kaskel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Combined growth hormone (GH) and insulin-like growth factor-I (IGF-I) therapy has been advocated for clinical use to minimize the diabetogenic effect of GH and enhance their anabolic effects. However, GH has been shown to accelerate the development of glomerular sclerosis in experimental animals and IGF-I mediates the renal effects of GH. The purpose of this study was therefore to examine morphometrically the effects of GH (1 mg intraperitoneally three times a week), IGF-I (50 μg/kg body weight subcutaneously twice a day), and combined GH/IGF-I treatments in vivo on mesangial matrix at 3-20 days after 5/6 nephrectomy in 140- to 150-g rats. There were no significant changes in growth and renal function after GH and/or IGF-I treatment. The effects of GH and IGF-I on glomerular size were additive, which were more prominent in juxtamedullary glomeruli. GH induced proportional increases in mesangial area (MA) and glomerular area (GA), whereas IGF-I induced a similar increase in GA without a corresponding change in MA. When compared with GH treatment alone, combined GH/IGF-I treatment resulted in a lesser degree of mesangial expansion despite an enhanced glomerular size. While additional studies are needed to examine the long-term effects of these findings, our results suggest a potentially beneficial effect of combined GH/IGF-I therapy during uremia.

Original languageEnglish (US)
Pages (from-to)299-303
Number of pages5
JournalPediatric Nephrology
Volume10
Issue number3
DOIs
StatePublished - Jun 1996
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Kidney
Anabolic Agents
Uremia
Sclerosis
Nephrectomy
Body Weight

Keywords

  • Growth hormone
  • Insulin-like growth factor-I
  • Mesangial matrix
  • Rats
  • Uremia

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Growth hormone and insulin-like growth factor-I and mesangial matrix in uremic rats. / Lin, Jen Jar; Fine, Richard N.; Kaskel, Frederick J.

In: Pediatric Nephrology, Vol. 10, No. 3, 06.1996, p. 299-303.

Research output: Contribution to journalArticle

@article{b79fd1e7ceb548388186fd26df57c7d3,
title = "Growth hormone and insulin-like growth factor-I and mesangial matrix in uremic rats",
abstract = "Combined growth hormone (GH) and insulin-like growth factor-I (IGF-I) therapy has been advocated for clinical use to minimize the diabetogenic effect of GH and enhance their anabolic effects. However, GH has been shown to accelerate the development of glomerular sclerosis in experimental animals and IGF-I mediates the renal effects of GH. The purpose of this study was therefore to examine morphometrically the effects of GH (1 mg intraperitoneally three times a week), IGF-I (50 μg/kg body weight subcutaneously twice a day), and combined GH/IGF-I treatments in vivo on mesangial matrix at 3-20 days after 5/6 nephrectomy in 140- to 150-g rats. There were no significant changes in growth and renal function after GH and/or IGF-I treatment. The effects of GH and IGF-I on glomerular size were additive, which were more prominent in juxtamedullary glomeruli. GH induced proportional increases in mesangial area (MA) and glomerular area (GA), whereas IGF-I induced a similar increase in GA without a corresponding change in MA. When compared with GH treatment alone, combined GH/IGF-I treatment resulted in a lesser degree of mesangial expansion despite an enhanced glomerular size. While additional studies are needed to examine the long-term effects of these findings, our results suggest a potentially beneficial effect of combined GH/IGF-I therapy during uremia.",
keywords = "Growth hormone, Insulin-like growth factor-I, Mesangial matrix, Rats, Uremia",
author = "Lin, {Jen Jar} and Fine, {Richard N.} and Kaskel, {Frederick J.}",
year = "1996",
month = "6",
doi = "10.1007/s004670050113",
language = "English (US)",
volume = "10",
pages = "299--303",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Growth hormone and insulin-like growth factor-I and mesangial matrix in uremic rats

AU - Lin, Jen Jar

AU - Fine, Richard N.

AU - Kaskel, Frederick J.

PY - 1996/6

Y1 - 1996/6

N2 - Combined growth hormone (GH) and insulin-like growth factor-I (IGF-I) therapy has been advocated for clinical use to minimize the diabetogenic effect of GH and enhance their anabolic effects. However, GH has been shown to accelerate the development of glomerular sclerosis in experimental animals and IGF-I mediates the renal effects of GH. The purpose of this study was therefore to examine morphometrically the effects of GH (1 mg intraperitoneally three times a week), IGF-I (50 μg/kg body weight subcutaneously twice a day), and combined GH/IGF-I treatments in vivo on mesangial matrix at 3-20 days after 5/6 nephrectomy in 140- to 150-g rats. There were no significant changes in growth and renal function after GH and/or IGF-I treatment. The effects of GH and IGF-I on glomerular size were additive, which were more prominent in juxtamedullary glomeruli. GH induced proportional increases in mesangial area (MA) and glomerular area (GA), whereas IGF-I induced a similar increase in GA without a corresponding change in MA. When compared with GH treatment alone, combined GH/IGF-I treatment resulted in a lesser degree of mesangial expansion despite an enhanced glomerular size. While additional studies are needed to examine the long-term effects of these findings, our results suggest a potentially beneficial effect of combined GH/IGF-I therapy during uremia.

AB - Combined growth hormone (GH) and insulin-like growth factor-I (IGF-I) therapy has been advocated for clinical use to minimize the diabetogenic effect of GH and enhance their anabolic effects. However, GH has been shown to accelerate the development of glomerular sclerosis in experimental animals and IGF-I mediates the renal effects of GH. The purpose of this study was therefore to examine morphometrically the effects of GH (1 mg intraperitoneally three times a week), IGF-I (50 μg/kg body weight subcutaneously twice a day), and combined GH/IGF-I treatments in vivo on mesangial matrix at 3-20 days after 5/6 nephrectomy in 140- to 150-g rats. There were no significant changes in growth and renal function after GH and/or IGF-I treatment. The effects of GH and IGF-I on glomerular size were additive, which were more prominent in juxtamedullary glomeruli. GH induced proportional increases in mesangial area (MA) and glomerular area (GA), whereas IGF-I induced a similar increase in GA without a corresponding change in MA. When compared with GH treatment alone, combined GH/IGF-I treatment resulted in a lesser degree of mesangial expansion despite an enhanced glomerular size. While additional studies are needed to examine the long-term effects of these findings, our results suggest a potentially beneficial effect of combined GH/IGF-I therapy during uremia.

KW - Growth hormone

KW - Insulin-like growth factor-I

KW - Mesangial matrix

KW - Rats

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=0029941265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029941265&partnerID=8YFLogxK

U2 - 10.1007/s004670050113

DO - 10.1007/s004670050113

M3 - Article

VL - 10

SP - 299

EP - 303

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 3

ER -